Literature DB >> 8523072

Primary central nervous system lymphomas--new pathological developments.

K A Jellinger1, W Paulus.   

Abstract

Primary central nervous system lymphomas (PCNSL) show increased incidence both in immunocompromised high-risk groups and in the general population. They are extranodal diffuse non-Hodgkin's lymphomas with a morphology similar to systemic lymphomas, but differ in their biological and molecular behaviour. The majority are large B-cell variants of high-grade malignancy; low-grade subtypes and T-cell lymphomas are rare; up to 50% remain unclassified according to the New Working Formulation and updated Kiel classification. Monoclonality of immunoglobulin receptor gene rearrangement can be diagnostically useful. The pathogenesis of PCNSL is obscure. Epstein-Barr virus (EBV) genome/proteins expression in two-thirds of HIV-related PCNSL but only in 15% of those in immunocompetent patients suggest different EBV latency stages in both types; human herpesvirus type 6 does not appear to play a pathogenic role. Comparison of expression patterns of integrin chains and adhesion molecules are very similar for PCNSL and nodal lymphomas suggesting that they are not selective mediators of lymphoma cell homing to the brain. In HIV-negative PCNSL they appear not to be influenced by EBV. Studies of protooncogenes (bcl-1 and bcl-2 genes) revealed no rearrangement in PCNSL, suggesting that they are not involved in the pathogenesis of PCNSL that probably do not differ cytogenetically from nodal B-cell lymphomas. Since most of the currently known molecular parameters are probably not the primary pathogenic events, the molecular genetics and pathogenesis of PCNSL are still to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8523072     DOI: 10.1007/bf01052655

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  20 in total

Review 1.  Primary cerebral malignant non-Hodgkin's lymphomas: a retrospective clinical study.

Authors:  D F Braus; K Schwechheimer; H K Müller-Hermelink; G Schwarzkopf; B Volk; F Mundinger
Journal:  J Neurol       Date:  1992-03       Impact factor: 4.849

2.  Human herpesvirus-6 and Epstein-Barr virus genome in primary cerebral lymphomas.

Authors:  W Paulus; K Jellinger; C Hallas; G Ott; H K Müller-Hermelink
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

3.  Primary central nervous system lymphomas. Immunophenotypic, virologic, and cytogenetic findings of three patients without immune defects.

Authors:  T Itoyama; N Sadamori; K Tsutsumi; Y Tokunaga; H Soda; M Tomonaga; S Yamamori; Y Masuda; K Oshima; M Kikuchi
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

4.  Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.

Authors:  S J Hamilton-Dutoit; D Rea; M Raphael; K Sandvej; H J Delecluse; C Gisselbrecht; L Marelle; H J van Krieken; G Pallesen
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

5.  Differential expression of cell adhesion molecules in B-zone small lymphocytic lymphoma and other well-differentiated lymphocytic disorders.

Authors:  A Pinto; A Carbone; A Gloghini; G Marotta; R Volpe; V Zagonel
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

6.  Comparison of integrin adhesion molecules expressed by primary brain lymphomas and nodal lymphomas.

Authors:  W Paulus; K Jellinger
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  Primary peripheral-postthymic T-cell lymphoma in the central nervous system: immunological and molecular approaches to diagnosis.

Authors:  T Nitta; K Uda; M Ebato; K Ikezaki; M Fukui; K Sato
Journal:  J Neurosurg       Date:  1995-01       Impact factor: 5.115

8.  Expression of a lymphocyte adhesion molecule (CD44) in malignant lymphomas: relevance to primary site, histological subtype and clinical stage.

Authors:  K Fujiwara; T Yoshino; K Miyake; N Ohara; T Akagi
Journal:  Acta Med Okayama       Date:  1993-06       Impact factor: 0.892

Review 9.  Large cell anaplastic (KI-1) brain lymphoma of T-cell genotype.

Authors:  W Paulus; M M Ott; H Strik; V Keil; H K Müller-Hermelink
Journal:  Hum Pathol       Date:  1994-11       Impact factor: 3.466

10.  National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.

Authors: 
Journal:  Cancer       Date:  1982-05-15       Impact factor: 6.860

View more
  9 in total

1.  Epidemiology of primary CNS lymphoma.

Authors:  M Schabet
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 2.  Glucocorticoid treatment of primary CNS lymphoma.

Authors:  M Weller
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

3.  Intracerebral Human Lymphoma - An Experimental Model.

Authors:  János Schnur; Andrea Ladányi; László Kopper
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 4.  Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.

Authors:  Rym Ben Abdelwahed Bagga; Sabrina Donnou; Jérémie Cosette; Catherine Sautès-Fridman; Mahjoub Aouni; Sylvain Fisson
Journal:  J Neurooncol       Date:  2014-10-10       Impact factor: 4.130

5.  Pathway analysis of primary central nervous system lymphoma.

Authors:  Han W Tun; David Personett; Karen A Baskerville; David M Menke; Kurt A Jaeckle; Pamela Kreinest; Brandy Edenfield; Abba C Zubair; Brian P O'Neill; Weil R Lai; Peter J Park; Michael McKinney
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

6.  [Primary cerebellar T-cell lymphoma].

Authors:  A Zimpfer; M Wasner; F Fend; M Tolnay; S Dirnhofer
Journal:  Pathologe       Date:  2008-07       Impact factor: 1.011

7.  High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.

Authors:  Cui Chen; Peng Sun; Juan Cui; Shumei Yan; Hao Chen; Yi Xia; Xiwen Bi; Panpan Liu; Yu Wang; Hang Yang; Man Nie; Xue-Wen Zhang; Wenqi Jiang; Zhi-Ming Li
Journal:  Cancer Med       Date:  2019-03-01       Impact factor: 4.452

8.  Primary peripheral T-cell central nervous system lymphoma.

Authors:  Cylaina E Bird; Jeffrey I Traylor; Jenna Thomas; James P Caruso; Benjamin Kafka; Flavia Rosado; Kyle M Blackburn; Kimmo J Hatanpaa; Kalil G Abdullah
Journal:  Surg Neurol Int       Date:  2021-09-13

9.  Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and "aggregoma": an update on classification and diagnosis.

Authors:  Marco Skardelly; Georgios Pantazis; Sotirios Bisdas; Guenther C Feigl; Martin U Schuhmann; Marcos S Tatagiba; Rainer Ritz
Journal:  BMC Neurol       Date:  2013-08-15       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.